These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 15736185)

  • 1. Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women.
    Wøjdemann KR; Shalmi AC; Christiansen M; Larsen SO; Sundberg K; Brocks V; Bang J; Nørgaard-Pedersen B; Tabor A
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):227-33. PubMed ID: 15736185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
    Alldred SK; Takwoingi Y; Guo B; Pennant M; Deeks JJ; Neilson JP; Alfirevic Z
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012600. PubMed ID: 28295158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free β-hCG and PAPP-A: a 5-year prospective study.
    Ghaffari SR; Tahmasebpour AR; Jamal A; Hantoushzadeh S; Eslamian L; Marsoosi V; Fattahi F; Rajaei M; Niroomanesh S; Borna S; Beigi A; Khazardoost S; Saleh-Gargari S; Rahimi-Sharbaf F; Farrokhi B; Bayani N; Tehrani SE; Shahsavan K; Farzan S; Moossavi S; Ramezanzadeh F; Dastan J; Rafati M
    Ultrasound Obstet Gynecol; 2012 May; 39(5):528-34. PubMed ID: 21793085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
    Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome.
    Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM
    Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective validation of first-trimester combined screening for trisomy 21.
    Kagan KO; Etchegaray A; Zhou Y; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Jul; 34(1):14-8. PubMed ID: 19526452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
    Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
    Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
    Herraiz I; López-Jiménez EA; García-Burguillo A; Nieto O; Villar OP; Escribano D; Galindo A
    Ultrasound Obstet Gynecol; 2009 May; 33(5):518-23. PubMed ID: 19402101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.